Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities
Pedro Moutinho-Ribeiro, Inês A. Batista, Sofía Torres Quintas, Bárbara Adem, Marco Silva, Rui Morais, Armando Peixoto, Rosa Coelho, Pedro Costa‐Moreira, Renato Medas, Susana Lopes, Filipe Vilas‐Boas, Manuela Baptista, Diogo Dias-Silva, Ana L Esteves, Filipa Martins, Joanne Lopes, Helena Barroca, Fátima Carneiro, Guilherme Macedo, Sónia A. Melo
Abstract
BACKGROUND: Individuals within specific risk groups for pancreatic ductal adenocarcinoma (PDAC) [mucinous cystic lesions (MCLs), hereditary risk (HR), and new-late onset diabetes mellitus (NLOD)] represent an opportunity for early cancer detection. Endoscopic ultrasound (EUS) is a premium image modality for PDAC screening and precursor lesion characterization. While no specific biomarker is currently clinically available for this purpose, glypican-1 (GPC1) is overexpressed in the circulating exosomes (crExos) of patients with PDAC compared with healthy subjects or those harboring benign pancreatic diseases. AIM: crExos to identify individuals at higher risk within these specific groups, all characterized by EUS. METHODS: 27.0 (IBM Corp., Armonk, NY, United States) version was used. All graphs were created using GraphPad Prism 7.00 (GraphPad Software, San Diego, CA, United States). RESULTS: = 0.012). CONCLUSION: crExos may act as biomarker to support the diagnosis and stratification of PDAC precursor lesions, and in signaling individuals with genetic predisposition in the absence of EUS abnormalities.